论文部分内容阅读
目的探讨替吉奥治疗中晚期肺癌的近期疗效和安全性。方法选择2010年1月至2012年4月收治的中晚期肺癌患者83例,按照随机数字表法分为观察组和对照组,对照组患者(40例)采用多西他赛联合顺铂治疗,观察组患者(43例)采用多西他赛联合替吉奥治疗,观察两组患者的治疗情况。结果观察组患者的有效率为81.4%,明显高于对照组的57.5%,差异有统计学意义(P<0.05)。治疗后两组患者的血清中肿瘤标志物癌胚抗原(CEA)、癌抗原125(CA125)、神经元特异性烯醇化酶(NSE)水平均明显改善,且观察组患者改善更为明显,组间差异均有统计学意义(P<0.05)。观察组患者不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论替吉奥治疗中晚期肺癌近期疗效满意,安全性可靠,能够明显改善患者血清肿瘤标志物CEA、CA125和NSE的水平。
Objective To investigate the short-term curative effect and safety of treatment of middle and late stage lung cancer for treatment of Gio. Methods From January 2010 to April 2012, 83 patients with advanced lung cancer who were admitted to our hospital from January 2010 to April 2012 were divided into observation group and control group according to random number table method. Patients in control group (40 cases) were treated with docetaxel plus cisplatin, Patients in the observation group (43 cases) were treated with docetaxel and tioguanide, and the treatment of both groups was observed. Results The effective rate of observation group was 81.4%, which was significantly higher than that of control group (57.5%), the difference was statistically significant (P <0.05). After treatment, the levels of CEA, CA125 and NSE in the serum of the two groups were significantly improved, and the improvement in the observation group was more obvious There was significant difference between the two groups (P <0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group, the difference was statistically significant (P <0.05). Conclusion Treatment of middle and late lung cancer with TIGO is satisfactory and safe in the near future. It can significantly improve the serum levels of CEA, CA125 and NSE in patients with advanced lung cancer.